ES2150888T1 - Diagnosis y tratamiento de la disenteria bacteriana. - Google Patents

Diagnosis y tratamiento de la disenteria bacteriana.

Info

Publication number
ES2150888T1
ES2150888T1 ES00101263T ES00101263T ES2150888T1 ES 2150888 T1 ES2150888 T1 ES 2150888T1 ES 00101263 T ES00101263 T ES 00101263T ES 00101263 T ES00101263 T ES 00101263T ES 2150888 T1 ES2150888 T1 ES 2150888T1
Authority
ES
Spain
Prior art keywords
gal
beta
treatment
slt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES00101263T
Other languages
English (en)
Inventor
Glen D Armstrong
R Murray Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synsorb Biotech Inc
Original Assignee
Synsorb Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synsorb Biotech Inc filed Critical Synsorb Biotech Inc
Publication of ES2150888T1 publication Critical patent/ES2150888T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

Uso de un agente en la preparación de un medicamento para la prevención o tratamiento de una infección entérica mediada por una SLT, en donde dicho agente es un soporte de afinidad inerte, sólido, farmacéuticamente aceptable, capaz de ser eliminado del tracto gastrointestinal, cuyo soporte tiene un ligando de afinidad enlazado covalentemente al mismo a través de un brazo separador, y en donde dicho ligando se caracteriza como un oligosacárido que contiene la subunidad disacárida Alfa Gal(1-4)Beta Gal que se une a la SLT; con la condición de que el disacárido no forma parte de un trisacárido Alfa Gal(1-4)Beta Gal(1-4)Beta GlcNAc o de un trisacárido Alfa Gal(1-4)Beta Gal(1-4)Beta Glc.
ES00101263T 1991-10-18 1992-10-19 Diagnosis y tratamiento de la disenteria bacteriana. Pending ES2150888T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77873291A 1991-10-18 1991-10-18

Publications (1)

Publication Number Publication Date
ES2150888T1 true ES2150888T1 (es) 2000-12-16

Family

ID=25114261

Family Applications (2)

Application Number Title Priority Date Filing Date
ES00101263T Pending ES2150888T1 (es) 1991-10-18 1992-10-19 Diagnosis y tratamiento de la disenteria bacteriana.
ES92922817T Expired - Lifetime ES2154265T3 (es) 1991-10-18 1992-10-19 Tratamiento de la disenteria bacteriana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES92922817T Expired - Lifetime ES2154265T3 (es) 1991-10-18 1992-10-19 Tratamiento de la disenteria bacteriana.

Country Status (9)

Country Link
US (3) US5620858A (es)
EP (2) EP0610356B1 (es)
AT (1) ATE198991T1 (es)
CA (1) CA2121604C (es)
DE (2) DE1018342T1 (es)
DK (1) DK0610356T3 (es)
ES (2) ES2150888T1 (es)
GR (1) GR3035665T3 (es)
WO (1) WO1993008209A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008209A1 (en) * 1991-10-18 1993-04-29 Chembiomed Ltd. Diagnosis and treatment of bacterial dysentery
US5484773A (en) * 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5661131A (en) * 1995-06-05 1997-08-26 Synsorb Biotech, Inc. Treatment of cholera
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US6069137A (en) * 1996-03-11 2000-05-30 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5891860A (en) * 1996-03-11 1999-04-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
JPH107575A (ja) * 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
CN1209752A (zh) * 1996-06-21 1999-03-03 辛索尔布生物技术有限公司 用于中和大肠杆菌毒素的寡糖的用途
US5846943A (en) * 1996-11-08 1998-12-08 Synsorb Biotech, Inc. Solid support matricles containing a toxin binding oligosaccharide
US6013634A (en) * 1996-11-08 2000-01-11 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
US5910579A (en) * 1997-01-10 1999-06-08 Synsorb Biotech Inc. Processes for the preparation of αGal(1->4)βGal (1->4) Glc-OR
US5888750A (en) * 1997-05-30 1999-03-30 Synsorb Biotech, Inc. Method of recovering shiga-like toxins and vaccines comprising inactivated shiga-like toxin
ZA991410B (en) 1998-02-23 1999-10-06 Synsorb Biotech Inc Compounds and methods for the treatment of bacterial dysentry using antibiotics and toxin binding oligosaccharide compositions.
NZ508172A (en) 1998-04-15 2003-08-29 Univ Utah State Real time detection of antigens
US7220596B2 (en) * 1998-04-15 2007-05-22 Utah State University Real time detection of antigens
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
US5962423A (en) * 1998-08-07 1999-10-05 The Governors Of The University Of Alberta Treatment of bacterial dysentery
US7135173B2 (en) * 2000-07-13 2006-11-14 Idaho Research Foundation, Inc. Antiviral activity of Shiga toxin
US6541013B1 (en) 2000-07-13 2003-04-01 Idaho Research Foundation, Inc. Methods and compositions for suppressing bovine leukemia virus with a Shiga toxin polypeptide
US20060051440A1 (en) * 2002-09-10 2006-03-09 Joel Moss Factors that bind intestinal toxins
BE1019290A5 (nl) * 2010-04-14 2012-05-08 Nutrition Sciences Nv Sa Voedingsupplement omvattende oligosachariden en middellange keten vetzuren.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347244A (en) * 1979-03-16 1982-08-31 Societe Anonyme Dite: Institut Merieux Ganglioside containing compositions for treating diarrhea
SE8001748L (sv) * 1980-03-05 1981-09-06 Kaellenius Gunilla Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik
EP0058665B1 (en) * 1980-05-09 1986-02-26 LEFFLER, Hakon Carbohydrate derivatives for inhibiting bacterial adherence
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
AU561067B2 (en) * 1982-03-22 1987-04-30 Biocarb Ab Anti-bacterial composition containing an oligosaccharide
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
SE8406626D0 (sv) * 1984-12-27 1984-12-27 Bio Carb Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte anvendning av sadan forening och komposition for terapeutisk behandling och isolering av shigatoxin
US4946943A (en) * 1985-06-20 1990-08-07 Will Bloch Purification of ribotoxins and their conjugates
US4863852A (en) * 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
US5168063A (en) * 1990-07-27 1992-12-01 Wisconsin Alumni Research Foundation Monoclonal antibody to enterohemorrhagic escherichia coli 0157:h7 and 026:h11
WO1993008209A1 (en) * 1991-10-18 1993-04-29 Chembiomed Ltd. Diagnosis and treatment of bacterial dysentery
AU667533B2 (en) * 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
US5484773A (en) * 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea

Also Published As

Publication number Publication date
WO1993008209A1 (en) 1993-04-29
EP1018342A2 (en) 2000-07-12
EP0610356A1 (en) 1994-08-17
DE1018342T1 (de) 2001-01-11
ATE198991T1 (de) 2001-02-15
EP0610356B1 (en) 2001-01-31
CA2121604A1 (en) 1993-04-29
US5679653A (en) 1997-10-21
EP1018342A3 (en) 2001-04-11
ES2154265T3 (es) 2001-04-01
DE69231675T2 (de) 2001-06-28
CA2121604C (en) 2002-01-15
GR3035665T3 (en) 2001-06-29
DE69231675D1 (de) 2001-03-08
DK0610356T3 (da) 2001-02-19
US5955449A (en) 1999-09-21
EP0610356A4 (en) 1995-03-29
US5620858A (en) 1997-04-15

Similar Documents

Publication Publication Date Title
ES2150888T1 (es) Diagnosis y tratamiento de la disenteria bacteriana.
KUNIN A guide to use of antibiotics in patients with renal disease: A table of recommended doses and factors governing serum levels
US5635606A (en) Method of binding and removing toxin A
Heerze et al. Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis
CA2460749A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
IL158088A (en) Use of an antibody linked to ailim for the preparation of a pharmacological preparation for suppressing or preventing inflammatory bowel disease
US6107282A (en) Treatment of C. difficile toxin B associated conditions
AU3042995A (en) Diagnostic testing for campylobacter jejuni or coli infection using antigens
Ertl et al. Nocardial endocarditis of an aortic valve prosthesis.
NZ302632A (en) Treatment of traveller's diarrhea using a pharmaceutical composition containing a saccharide sequence
US6358930B1 (en) Treatment of C. difficile toxin B associated conditions
Gaut et al. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections
Proctor Editorial response: coagulase-negative staphylococcal infections: A diagnostic and therapeutic challenge
Chidiac et al. Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens
Berti et al. Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections
Geddes et al. Co-trimoxazole for the treatment of serious infections
WO1997049431A3 (en) Use of oligosaccharides for neutralising e. coli toxins
NZ332434A (en) Use of oligosaccharide compositions which bind one or more serotypes of cholerae toxin in the intestinal tract for the treatment of cholera and related conditions
Patro et al. Gas forming pyogenic liver abscess in a diabetic patient: a rare case report
Vincent et al. Experience with Tobramygin and Cephalothin Sodium in Infected Patients with Acute Leukaemia (AL)
Abrahm Management of the immunocompromised host
Farthing Gut infections
Yu Chemically-modified tetracycline: absorption, serum half-life, and effect on collagen metabolism
FR2895899B1 (fr) Systeme d'imagerie medicale.
Mayfield et al. Ward environment and the severely regressed patient.